Literature DB >> 10591539

Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates.

D Hall1, G Ybazeta, G Destro-Bisol, M L Petzl-Erler, A Di Rienzo.   

Abstract

Variation at the UDP-glucuronosyltransferase (UGT) 1A1 gene promoter is present in humans. Variable numbers of TA repeats in the TATA box of this gene are found which are inversely related to levels of gene expression. We investigated this polymorphism in 658 individuals from a worldwide sample of 15 aboriginal and two admixed human populations. This study shows that there is a great deal of variability across ethnic groups with regard to UGT1A1 allele frequencies, with the most common allele varying in frequency from 33% to 91%. Populations of African origin harbor four different alleles while non-African populations appear to have only two alleles. In addition, alleles associated with lower gene expression levels reach the highest frequencies in populations of African origin and lowest among Asians and Amerindians. Thus, more variability in the metabolism of drugs eliminated by UGT1A1 glucuronidation should be expected in populations of Sub-Saharan African origin. The sequence analysis of nine primate species shows that the number of TA repeats has increased during primate evolution achieving the largest number in humans. We suggest that the UGT1A1 promoter variability does not reflect historical relationships between populations and that it may be maintained by natural selection. Our findings are consistent with the proposal that the TA repeat variation is a balanced polymorphism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10591539

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  31 in total

Review 1.  The role of pharmacogenetics in cancer therapeutics.

Authors:  Wei Peng Yong; Federico Innocenti; Mark J Ratain
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

2.  The effect of UGT1A1 promoter polymorphism in the development of hyperbilirubinemia and cholelithiasis in hemoglobinopathy patients.

Authors:  Suad AlFadhli; Hassan Al-Jafer; Mays Hadi; Mashael Al-Mutairi; Rasheeba Nizam
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

3.  Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing.

Authors:  Smita S Joshi; Daniel V T Catenacci; Theodore G Karrison; Jaclyn D Peterson; Mark M Zalupski; Amikar Sehdev; James Wade; Ahad Sadiq; Vincent J Picozzi; Andrea Amico; Robert Marsh; Mark F Kozloff; Blase N Polite; Hedy L Kindler; Manish R Sharma
Journal:  Clin Cancer Res       Date:  2019-09-26       Impact factor: 12.531

4.  Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.

Authors:  Federico Innocenti; Richard L Schilsky; Jacqueline Ramírez; Linda Janisch; Samir Undevia; Larry K House; Soma Das; Kehua Wu; Michelle Turcich; Robert Marsh; Theodore Karrison; Michael L Maitland; Ravi Salgia; Mark J Ratain
Journal:  J Clin Oncol       Date:  2014-06-23       Impact factor: 44.544

5.  Is there diversity among UGT1A1 polymorphism in Japan?

Authors:  Michiya Kobayashi; Shoichi Hazama; Kenichi Takahashi; Koji Oba; Naoko Okayama; Mitsuaki Nishioka; Yuji Hinoda; Masaaki Oka; Ken Okamoto; Hiromichi Maeda; Daisuke Nakamura; Junichi Sakamoto; Hideyuki Mishima
Journal:  World J Gastrointest Oncol       Date:  2012-07-15

Review 6.  Pharmacogenetics: a tool for individualizing antineoplastic therapy.

Authors:  F Innocenti; L Iyer; M J Ratain
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 7.  Pharmacogenomic progress in individualized dosing of key drugs for cancer patients.

Authors:  Christine M Walko; Howard McLeod
Journal:  Nat Clin Pract Oncol       Date:  2009-01-27

Review 8.  Gene replacement therapy for genetic hepatocellular jaundice.

Authors:  Remco van Dijk; Ulrich Beuers; Piter J Bosma
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 9.  UGT genotyping in belinostat dosing.

Authors:  Andrew K L Goey; William D Figg
Journal:  Pharmacol Res       Date:  2016-01-07       Impact factor: 7.658

10.  Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers.

Authors:  Y K Pithavala; M Tortorici; M Toh; M Garrett; B Hee; U Kuruganti; G Ni; K J Klamerus
Journal:  Cancer Chemother Pharmacol       Date:  2009-07-15       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.